Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004262 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
A Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, sponsored by Aduro Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
- 20
- Study locations
NCT02004262: Completed Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, sponsored by Aduro Biotech.
NCT02004262 is a Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer that has completed, run by Aduro Biotech. The registered enrollment target is 303 participants. The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02004262, a Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, has completed, sponsored by Aduro Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
- 20
- Study locations
Study Summary
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG cyclophosphamide
- BIOLOGICAL GVAX Pancreas Vaccine
- BIOLOGICAL CRS-207
Study Locations (20)
California
- University California San Diego Moores Cancer Center - La Jolla
- University of California Mt Zion Comprehensive Cancer Center - San Francisco
- University of California Los Angeles - Santa Monica
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
Arizona
- Scottsdale Healthcare Research Institute - Scottsdale
Colorado
- University of Colorado Denver - Aurora
Florida
- University of Miami/Sylvester Cancer Center - Miami
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2014-02-05 |
| Est. Completion | 2016-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02004262
The ClinicalTrials.gov registry entry for NCT02004262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Chemotherapy is the first listed.
NCT02004262 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT02004262 about?
NCT02004262 is a clinical study titled "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting". Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
What is the current status of trial NCT02004262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2014-02-05. Estimated completion is 2016-08-23.
What conditions does trial NCT02004262 study?
This clinical trial studies the following conditions: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT02004262?
The interventions under investigation include: Chemotherapy (DRUG), cyclophosphamide (DRUG), GVAX Pancreas Vaccine (BIOLOGICAL), CRS-207 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02004262?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02004262 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.